Skip to main content

For US Healthcare Professionals only

Beyfortus® logo
For OB-GYNS
Dosing & Administration

Resources

Explore comprehensive downloadable resources and tools designed to aid you in improving Beyfortus® (nirsevimab-alip) uptake in your practice.

Tools for your practice
For parents
For nurses
For OB-GYNS
Additional resources
Contact & sign up

Tools for your practice

For parents

Give your baby an extra layer of protection against RSV when they need it most; RSV: Respiratory Syncytial Virus

RSV educational brochure

Educate parents on the basics of RSV disease and how Beyfortus can help protect their infant or child (<24 months of age).

Download in EnglishDownload in Spanish
Beyfortus® (nirsevimab-alip) RSV basics flyer thumbnail

RSV basics flyer

A brief flyer to educate parents on the basics of RSV disease and the protection offered by Beyfortus.

Download in EnglishDownload in Spanish

For nurses

Beyfortus® (nirsevimab-alip) before the season brochure for nurses thumbnail

Brochure

Before the season brochure

Key talking points regarding the risks of RSV and recommendations for the optimal time to discuss and administer Beyfortus.

Download Brochure
Beyfortus® (nirsevimab-alip) protocol checklist for nurses thumbnail

Checklist

Protocol checklist

A protocol checklist to help prepare for the RSV season and recall those older infants who need Beyfortus administration at the start of the RSV season.

Download Checklist
Beyfortus® (nirsevimab-alip) RSV season poster for nurses thumbnail

Poster

RSV season poster

An infographic poster that serves as a quick reference visual guide—reinforcing understanding of RSV risk, seasonality, and how Beyfortus works.

Download Poster

For OB-GYNS

Consider these useful resources and materials for Beyfortus to help ensure a seamless integration into your practice.

Beyfortus® (nirsevimab-alip) direct administration brochure for OB-GYNs thumbnail

OB-GYN brochure

Direct administration brochure

A useful resource about Beyfortus for OB-GYNS and their practice.

Download Brochure
Beyfortus® (nirsevimab-alip) parental counseling brochure for OB-GYNs thumbnail

OB-GYN brochure

Parental counseling brochure

A guide for educating parents on how Beyfortus can help protect newborns.

Download Brochure
Beyfortus® (nirsevimab-alip) second pregnancy RSV guidance for OB-GYNs thumbnail

OB-GYN brochure

Second pregnancy RSV guidance

Guidance on immunization to help protect infants if the mother has already received a respiratory syncytial virus maternal immunization during a previous pregnancy.

Download Brochure

Looking for information tailored to OB-GYNS?

Visit OB-GYN Page

Additional resources

Flyer

Second season immunization

A resource for identifying which infants might need additional protection for their second RSV season.

Download Flyer

Brochure

What you need to know: Beyfortus and Abrysvo®

Guidance and information for protecting infants without immunity provided by maternal vaccination.

Download Brochure

 

Year-round ordering flyer

Region-specific guidance for RSV immunization in infants and children.

Download for AlaskaDownload for FloridaDownload for Hawaii

Frequently asked questions

Explore FAQs

Order Beyfortus

Learn About Ordering

Cost & coverage

View Access Information

Contact & sign up

Keep informed with email updates

Sign up to get the latest information on Beyfortus.

Sign Up

Reach out to our team for support

Request a Sanofi representative to learn more about Beyfortus.

Request a Representative

EHR, electronic health record; RSV, respiratory syncytial virus.

Important Safety Information

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Indication

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Please see full Prescribing Information.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

Important Safety Information

Indication

MAT-US-2310577-v8.0-06/2026

Back to top
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContactAccessibility Statement
© 2026 Sanofi. All rights reserved.